Down 29.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Myriad (MYGN)

Myriad (MYGN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Investment Research • 19 hours ago

Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life

SALT LAKE CITY, May 15, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, joins forces with Nobody Wants This actress Jackie Tohn to raise awareness about the importance of hereditary cancer testing with the MyRisk ® Hereditary Cancer Test. Through conversations with her physician and genetic testing, Tohn discovered she carried a BRCA1 gene variant after her father was diagnosed with cancer and tested positive for the same variant.

GlobeNewsWire • May 15, 2026

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

SALT LAKE CITY, May 07, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences. The BofA Securities 2026 Health Care Conference – 1-to-1 investor meetings taking place Wednesday, May 13, 2026.

GlobeNewsWire • May 7, 2026

Myriad Genetics, Inc. (MYGN) Q1 2026 Earnings Call Transcript

Myriad Genetics, Inc. (MYGN) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 6, 2026

Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business

Highl ights First quarter 2026 revenue of $200.4 million grew 2% year-over-year, reflecting stable test volume and 2% year-over-year growth in average revenue per test. First quarter 2026 test volume reflects 13% and 7% test volume growth year-over-year in Cancer Care Continuum and Mental Health, respectively, offset by a 12% decline year-over-year in Prenatal Health test volume.

GlobeNewsWire • May 5, 2026

Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates

Myriad Genetics (MYGN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.03 per share a year ago.

Zacks Investment Research • May 6, 2026

Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan

The latest GeneSight® Mental Health Monitor from Myriad Genetics reveals that Americans feel mental health treatment isn't designed with them in mind.

GlobeNewsWire • Apr 30, 2026

Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026

SALT LAKE CITY, April 28, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its first quarter 2026 earnings conference call at 4:30 pm ET on Tuesday, May 5, 2026. The company's quarterly earnings will be released the same day after the market closes.

GlobeNewsWire • Apr 28, 2026

Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for

Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Apr 28, 2026

Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026

SALT LAKE CITY, April 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced that it will share six abstracts, including two podium presentations, at the American Association for Cancer Research (AACR) Annual Meeting 2026. "AACR is one of the premier forums for oncology research, and we are excited to share the depth of work underway across our MRD and hereditary cancer programs, including two podium presentations demonstrating the exceptional performance of Precise MRD, Myriad's tumor-informed, ultrasensitive MRD assay," said Dale Muzzey, PhD, Chief Scientific Officer, Myriad Genetics.

GlobeNewsWire • Apr 16, 2026